Pneumologie 2009; 63 - V146
DOI: 10.1055/s-0029-1214069

Multidrug- and extensively-drug resistant tuberculosis: a TBNET survey in Germany

B Eker 1, J Ortmann 2, G Migliori 3, G Sotgiu 4, R Mütterlein 5, R Centis 3, H Hoffmann 6, D Kirsten 7, T Schaberg 8, S Ruesch-Gerdes 1, C Lange 1
  • 1Research Center Borstel
  • 2Klinikum Gera
  • 3Fondazione S. Maugeri, WHO Collaborating Center for TB and Lung Diseases, Tradate, Italy
  • 4Hygiene and Preventive Medicine Institute, Sassari University, Sassari, Italy
  • 5Krankenhaus Pasberg
  • 6Asklepios-Klinik Gauting
  • 7Hospital Großhansdorf
  • 8Deakoness Hospital, Rotenburg

We evaluated risk factors and treatment outcomes associated with multidrug-resistant (MDR)- and extensively drug-resistant (XDR)-tuberculosis (TB) in Germany in 2004–2006. In 184/4,557 (4%) of culture-positive TB cases, M. tuberculosis isolates were MDR. 148/184 (80%) patients with MDR-TB were born in countries of the former Soviet Union. 7/184 (4%) met XDR-TB criteria. In patients with XDR-TB hospitalization was longer (mean±SD 202±130 vs. 123±81 days; p=0.015) and resistance to all first line drugs was more frequent (36% vs. 86%; p=0.013) than in patients with MDR-TB. 74/184 (40%) patients received treatment with linezolid. Treatment success rates ranged from 59.2% for the entire cohort (59.3% for MDR-TB and 57.1% for XDR-TB) to 87.2% for those with a definitive outcome (n=125; 87.5% for MDR-TB and 80% for XDR-TB). Extensive antibiotic susceptibility testing and availability of second- and third-line drugs under inpatient management conditions allow achieving relatively high treatment success rates in MDR- and XDR-TB.